Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             353 results found
no title author magazine year volume issue page(s) type
1 Editorial Board
32 S3 p. i
 article
2 LBA-4 Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer Janjigian, Y.
32 S3 p. S227
 article
3 LBA-3 Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR +/- MEK inhibitors Élez, E.
32 S3 p. S226-S227
 article
4 LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival Tempero, M.
32 S3 p. S226
 article
5 LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer Wainberg, Z.
32 S3 p. S227-S228
 article
6 LBA P-298 Response to total neoadjuvant therapy and survival in patients with early onset locally advanced rectal cancer Lumish, M.
32 S3 p. S228
 article
7 O-10 ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E–mutant metastatic colorectal cancer Van Cutsem, E.
32 S3 p. S222
 article
8 O-4 Average cumulative relative dose of adjuvant chemotherapy is more important than average relative dose intensity for colorectal cancer survival, with implications for treating obese patients: The OCTOPUS consortium Slawinski, C.
32 S3 p. S218-S219
 article
9 O-3 Characterization of KRAS mutation variants and prevalence of KRAS-G12C in gastrointestinal malignancies Salem, M.
32 S3 p. S218
 article
10 O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma Shitara, K.
32 S3 p. S224
 article
11 O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer André, T.
32 S3 p. S220-S221
 article
12 O-7 FOLFIRI ± napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study Shah, M.
32 S3 p. S220
 article
13 O-5 Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection Janjigian, Y.
32 S3 p. S219
 article
14 O-9 5-FU/LV + cetuximab + vemurafenib as maintenance therapy for BRAF-mutant (BRAFmut) metastatic colorectal cancer: Efficacy, safety, and exploratory biomarker findings from Cohort 1 of the MODUL trial Ducreux, M.
32 S3 p. S221-S222
 article
15 O-6 Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial Takahashi, N.
32 S3 p. S219-S220
 article
16 O-13 Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08) Sunakawa, Y.
32 S3 p. S223-S224
 article
17 O-16 HEPANOVA: Final efficacy and safety results from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma Gkika, E.
32 S3 p. S225
 article
18 O-11 Monitoring molecular residual disease by circulating tumor DNA in resectable colorectal cancer: Molecular subgroup analyses of a prospective observational study GALAXY in CIRCULATE-Japan Shirasu, H.
32 S3 p. S222-S223
 article
19 O-2 Overall survival and long-term safety data from the NETTER-1 trial: 177-Lu-Dotatate vs. high-dose octreotide in patients with progressive midgut NETs Strosberg, J.
32 S3 p. S217-S218
 article
20 O-12 Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: The AVANA study Salvatore, L.
32 S3 p. S223
 article
21 O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup Ajani, J.
32 S3 p. S225
 article
22 O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma Ducreux, M.
32 S3 p. S217
 article
23 P-144 A comparative analysis of secondary data from the ToGA and EVIDENCE studies on the effectiveness of trastuzumab plus chemotherapy in Asian patients with HER2+ metastatic gastric cancer Shen, L.
32 S3 p. S148
 article
24 P-269 Advanced gastric cancer bleeding: Association of hemostatic radiotherapy and iron supplementation - Is there a survival benefit? Laranja, A.
32 S3 p. S189
 article
25 P-156 A European chart review of treatment patterns and outcomes for patients with resected esophageal cancer or gastroesophageal junction cancer Singh, P.
32 S3 p. S152-S153
 article
26 P-56 A multicenter prospective translational study using circulating tumor DNA to identify acquired genomic alterations in recurrent gastric or gastroesophageal junction adenocarcinoma in patients who received curative-intent treatment (Liquid-GEAR) Takeda, H.
32 S3 p. S115-S116
 article
27 P-176 A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04) Sahai, V.
32 S3 p. S160
 article
28 P-182 A multicenter study of prognostic factors in nivolumab monotherapy for advanced or recurrent esophageal cancer Ikoma, T.
32 S3 p. S162
 article
29 P-19 A multicentred phase II clinical trial on yttrium 90-resin microspheres followed by gemcitabine-cisplatin for treatment of locally advanced intra-hepatic cholangiocarcinoma Chan, S.
32 S3 p. S102
 article
30 P-96 Analysis of three biographical times of disease in the IMbrave 150 study: A new measure to assess clinical effect Ceballos Barbancho, E.
32 S3 p. S130
 article
31 P-45 An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer Raghav, K.
32 S3 p. S111
 article
32 P-72 A patient preference study on risk thresholds to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma Parikh, N.
32 S3 p. S121-S122
 article
33 P-200 A phase II study of dose reductive XELOX plus bevacizumab in elderly or vulnerable patients with metastatic colorectal cancer: MCSGO-1202 Nakata, K.
32 S3 p. S168
 article
34 P-100 A phase II study of first-line chemotherapy initiating FOLFIRI+cetuximab and switching to FOLFIRI+bevacizumab according to early tumor shrinkage at 8 weeks in RAS wild-type metastatic colorectal cancer: HYBRID trial Shoji, H.
32 S3 p. S132
 article
35 P-140 A phase I study of biweekly abraxane in combination with oxaliplatin and oral S-1/leucovorin as first line treatment for advanced gastric, pancreatic and biliary tract cancers Tsai, H.
32 S3 p. S146-S147
 article
36 P-155 A phase I study of FLOT as first-line therapy for Japanese patients with advanced gastric cancer including patients with or without severe peritoneal metastasis Shiraishi, K.
32 S3 p. S152
 article
37 P-139 A phase 2 multicohort study (LEAP-005) of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Pancreatic cancer cohort Chung, H.
32 S3 p. S146
 article
38 P-24 A prospective phase 1b dose de-escalation open-label clinical study to evaluate the safety and efficacy of sorafenib with metformin and atorvastatin in advanced hepatocellular carcinoma (SMASH) Bhargava, P.
32 S3 p. S104
 article
39 P-185 A prospective, randomized, controlled, multicenter phase III clinical trial of apatinib combined with neoadjuvant chemoradiotherapy for patients with locally advanced, HER2-negative, Siewert’s type II-III adenocarcinoma of esophagogastric junction Zhao, Q.
32 S3 p. S163
 article
40 P-243 A prospective study to assess the impact of colostomy on psychosocial aspects of quality of life in colorectal cancer patients Khosla, D.
32 S3 p. S181-S182
 article
41 P-154 A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 Tabernero, J.
32 S3 p. S151-S152
 article
42 P-25 A review of circulating exosomal biomarkers in the diagnosis of pancreatic cancer Sha, M.
32 S3 p. S104
 article
43 P-98 A single-arm study of apatinib plus neoadjuvant chemotherapy followed by resection in patients with locally advanced colorectal adenocarcinoma Zhang, T.
32 S3 p. S131
 article
44 P-157 Assessing fitness for systemic therapy in hepatocellular carcinoma: Evaluating time on treatment according to Child-Pugh classification, model for end-stage liver disease score, and AFP level Staum, B.
32 S3 p. S153
 article
45 P-170 Assessment of long-term outcomes and predictive factors of malignancy in branch-duct intraductal papillary mucinous neoplasms: A retrospective study in a Canadian referral center Chennouf, A.
32 S3 p. S157-S158
 article
46 P-286 Assessment of the quality of life of patients with colorectal cancer in the Tunisian Center: A report of 142 patients Ben Moussa, C.
32 S3 p. S194
 article
47 P-103 Associations between quality-of-life, symptom burden, and demographic characteristics in long-term esophageal and gastroesophageal junction cancer survivors McGillivray, E.
32 S3 p. S133
 article
48 P-126 Atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma and chronic hepatitis B virus infection with high viral load Chen, S.
32 S3 p. S141-S142
 article
49 P-51 Baseline characteristics of patients enrolled in the CAPSTAN study: A European retrospective study in BRAFV600E-mutant metastatic colorectal cancer patients Martinelli, E.
32 S3 p. S113
 article
50 P-199 Baseline neutrophil to lymphocyte ratio predicts survival in patients with metastatic colorectal cancer treated with cetuximab plus avelumab (CAVE) as a rechallenge strategy Ciardiello, D.
32 S3 p. S167-S168
 article
51 P-259 Bone scan in gastrointestinal cancer Ghomari, C.
32 S3 p. S186
 article
52 P-209 Cancers of the bile duct: A study of 30 cases Benamar, W.
32 S3 p. S170
 article
53 P-210 Capecitabine and temozolomide for metastatic neuroendocrine neoplasms: A single-center “real-word” data analysis Caetano, A.
32 S3 p. S171
 article
54 P-125 Caring for more than survival: A survey of patient preferences in advanced hepatocellular carcinoma Sharma, R.
32 S3 p. S141
 article
55 P-278 Checkpoint inhibitors in patients with advanced, refractory biliary tract cancers Liddell, S.
32 S3 p. S192
 article
56 P-192 Chemoradiation for anal canal carcinoma: A multicentric retrospective cohort study Leão, I.
32 S3 p. S165
 article
57 P-99 Circulating RNA detection, circulating tumor cells count, and molecular tumor profiling in a cohort of untreated metastatic colorectal cancer: A prospective multicenter ancillary study to the randomized VISNÚ trials Valladares-Ayerbes, M.
32 S3 p. S131-S132
 article
58 P-108 Circulating tumor DNA for early relapse detection and monitoring disease status in patients with early-stage pancreatic adenocarcinoma Abdelrahim, M.
32 S3 p. S135
 article
59 P-114 Claudin 18 isoform expression in gastric adenocarcinoma and pancreatic adenocarcinoma Saito, T.
32 S3 p. S138
 article
60 P-237 Clinical doctors’ attitudes towards colorectal cancer genetic testing: A national multi-center cross-sectional study Liu, Y.
32 S3 p. S179-S180
 article
61 P-258 Clinical study of PD-1 disrupted anti-MUC1 CAR-T cells in patients with advanced oesophageal cancer Chen, S.
32 S3 p. S186
 article
62 P-146 Clinical usefulness of next generation sequencing by liquid biopsy for advanced gastric cancer Matsumoto, T.
32 S3 p. S149
 article
63 P-225 Clinico-epidemiological and therapeutic profile of rectal cancer: Experience of the department of radiation oncology EHSO ORAN Cheriguene, M.
32 S3 p. S176
 article
64 P-238 Clinicopathological profile and prognostic factors impacting survival of periampullary carcinoma: A tertiary care centre experience Singla, A.
32 S3 p. S180
 article
65 P-90 Combined high expression of MAP17 and fascin-1 in colorectal cancer: Targeted therapy in need? Tampakis, A.
32 S3 p. S128
 article
66 P-227 Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis Cai, Z.
32 S3 p. S176-S177
 article
67 P-165 Comparative study on the clinical effect of hand-assisted laparoscopic and laparoscopic gastrectomy for gastric stromal tumor Zhang, Q.
32 S3 p. S156
 article
68 P-246 Comparison of microbiome diversity in gastric cancer patients and in non-cancerous patients Bang, E.
32 S3 p. S182-S183
 article
69 P-112 Compliance analysis of biological samples and questionnaire collection in a colorectal cancer microbiome study: The VHIO experience Napoli, S.
32 S3 p. S137
 article
70 P-179 Complications of the rescue esophagectomy in advanced esophageal cancer Braga de Aquino, J.
32 S3 p. S161
 article
71 P-242 Comprehensive assessment of systemic and local immunity and clinical indicators in patients with gastric cancer Khakimova, G.
32 S3 p. S181
 article
72 P-129 Concomitant RAS and BRAF mutations: Impact on overall survival and progression free survival in metastatic colorectal cancer patients Pretta, A.
32 S3 p. S142-S143
 article
73 P-20 Concurrent chemo-radiotherapy in anal squamous cell carcinomas: A 10-year retrospective review of a tertiary centre experience Elmasry, A.
32 S3 p. S102-S103
 article
74 P-239 Consensus molecular subtypes of morphological regions on colorectal tumors Popovici, V.
32 S3 p. S180
 article
75 P-55 Constructing hybrid control for the Morpheus metastatic colorectal cancer trial using IMblaze370 historical trial data Li, C.
32 S3 p. S115
 article
76 P-43 C677T and A1298C MTHFR gene polymorphisms and response to fluoropyrimidine-based chemotherapy in mestizo patients with metastatic colorectal cancer Ramos-Esquivel, A.
32 S3 p. S110
 article
77 P-17 CT colonography: A minimally invasive screening option for colorectal cancer Grewal, J.
32 S3 p. S101
 article
78 P-173 Customisation of therapeutic strategy in metastatic colorectal cancer by use of liquid biopsies: Final results of an observational study Kastrisiou, M.
32 S3 p. S158-S159
 article
79 P-109 CYTOFLOC: Evaluation of a non-endoscopic immunocytological device (Cytosponge™) for post-chemo-radiotherapy surveillance in patients with oesophageal cancer – a feasibility study Mukherjee, S.
32 S3 p. S135-S136
 article
80 PD-4 A phase I trial of trifluridine/tipiracil in combination with nanoliposomal irinotecan in advanced GI cancers Alese, O.
32 S3 p. S200
 article
81 P-158 Deciphering the immunological determinants of response to neoadjuvant chemo-radiation in esophageal adenocarcinoma Arbore, G.
32 S3 p. S153
 article
82 P-107 Dermatopathological review of cutaneous squamous cell carcinoma events in patients with gastrointestinal stromal tumors treated with ripretinib Patel, A.
32 S3 p. S134-S135
 article
83 P-106 Descriptive study of long-term survivors with advanced pancreatic cancer Aviñó Tarazona, V.
32 S3 p. S134
 article
84 P-136 Detecting panitumumab/FOLFOX responders in K-Ras wild-type metastatic colorectal cancer through an artificial intelligence-based analytical tool Galmarini, C.
32 S3 p. S145
 article
85 P-253 Detection of potential molecules that might be implicated in colorectal metastasis to lung Apostolou, P.
32 S3 p. S184
 article
86 P-236 Determination of PD-L1 and MSI in ampullary carcinomas Eremeeva, E.
32 S3 p. S179
 article
87 P-248 Determination of the optimal electrical field for apoptosis in the rat stomach during irreversible electroporation Park, G.
32 S3 p. S183
 article
88 P-277 Development of an immune-related gene prognostic index for esophageal squamous cell carcinoma Ji, Q.
32 S3 p. S192
 article
89 PD-2 Final result of phase IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer Kim, R.
32 S3 p. S199
 article
90 P-15 Diagnostic potential of erythrocyte and serum fatty acids in spotting adenomatous polyps and identifying the early stages of colorectal cancer depending on tumor localization Kruchinina, M.
32 S3 p. S101
 article
91 P-168 Differences in coping strategies used by colorectal vs. non-colorectal cancer patients: Data from the Neoetic-SEOM study Pacheco-Barcia, V.
32 S3 p. S157
 article
92 P-222 Dihydropyrimidine dehydrogenase deficiencies and fluoropyrimidine toxicities: A study in the Tunisian Center Melliti, R.
32 S3 p. S175
 article
93 PD-3 Impact of RAS status, prior targeted therapy, age, and gender on the activity of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer: Real-world data from the QoLiTrap study von Moos, R.
32 S3 p. S199-S200
 article
94 PD-1 MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress) Siena, S.
32 S3 p. S199
 article
95 P-171 Does metastasectomy really improve survival in gastric cancer? Moura, F.
32 S3 p. S158
 article
96 P-145 Doublet regimen plus anti-vascular endothelial growth factor drug regimen after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer Matsumoto, T.
32 S3 p. S148-S149
 article
97 P-60 Doxycycline as preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy Ramirez Daffos, P.
32 S3 p. S117
 article
98 PD-6 Prediction of patients at high risk of upper gastrointestinal cancer for endoscopy using artificial intelligent technology Lin, Y.
32 S3 p. S201
 article
99 PD-5 Retrospective comparative analysis of K-ras G12C vs other K-ras mutations in metastatic colorectal cancer patients treated with first-line chemotherapy doublet + bevacizumab Giampieri, R.
32 S3 p. S200
 article
100 P-177 Early onset colorectal cancer outcomes in a public Uruguayan cancer centre Fontes, S.
32 S3 p. S160
 article
101 P-175 Effectiveness, prognostic factors and safety concerning ablative techniques in liver metastases from gastrointestinal tumors Gomez-Randulfe Rodriguez, M.
32 S3 p. S159-S160
 article
102 P-76 Effect of educational activity on the knowledge of oncologists regarding the latest clinical trial data investigating immunotherapy combination regimens for the frontline treatment of patients with unresectable HCC Dorkhom, N.
32 S3 p. S123
 article
103 P-121 Efficacy and toxicity of biosimilar and original bevacizumab in the second-line treatment of metastatic colon cancer in routine clinical practice: Results of an observational multicenter study Fedyanin, M.
32 S3 p. S140
 article
104 P-13 Efficacy of FOLFOX4 regimen with advanced hepatocellular carcinoma and prognostic factors for survival Chayangsu, C.
32 S3 p. S100
 article
105 P-167 Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients Xiao, B.
32 S3 p. S156
 article
106 P-235 E-health monitoring during pancreatic cancer treatment Jorge, T.
32 S3 p. S179
 article
107 P-58 Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: A multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria – BERING CRC Stintzing, S.
32 S3 p. S116
 article
108 P-250 Epidemiological, diagnostic and therapeutic profile of pancreatic cancer: Experience of a medical oncology department Chaibdra Tani, S.
32 S3 p. S183-S184
 article
109 P-147 Epigenetic gene somatic mutations in gastric cancer Kalinkin, A.
32 S3 p. S149
 article
110 P-296 Establishment of adoptive cell therapy with tumor-infiltrating lymphocytes for liver and oesophageal cancer Ma, S.
32 S3 p. S197-S198
 article
111 P-245 Evaluation of colon-specific plasma nanovesicles as new markers of colorectal cancer Nazarova, I.
32 S3 p. S182
 article
112 P-275 Evaluation of radical chemoradiation outcomes in stage II/III anal cancer: Real-world data population Fernandes, I.
32 S3 p. S191
 article
113 P-95 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancers Muro, K.
32 S3 p. S130
 article
114 P-66 Experience in our center of bone events not related to the disease in patients with locally advanced or metastatic adenocarcinoma of the pancreas Gallego Jimenez, I.
32 S3 p. S119
 article
115 P-23 Experience of concurrent chemoradiotherapy for pancreatic cancer in a large university hospital Searle, G.
32 S3 p. S104
 article
116 P-28 Exploratory analysis of patients with gastric/GEJ adenocarcinoma with or without liver metastasis from the phase 3 RAINBOW study Ogata, T.
32 S3 p. S105-S106
 article
117 P-274 Exploratory analysis of potential clinical, molecular and analytical prognostic factors of real-world patients with gastrointestinal stromal tumors: A single center study Perez Criado, I.
32 S3 p. S191
 article
118 P-284 Exploratory magnetic resonance imaging histogram biomarkers for response prediction to neoadjuvant treatment in oesophageal/gastro-oesophageal cancer Owczarczyk, K.
32 S3 p. S193-S194
 article
119 P-181 Exploratory randomized phase II trial for optimizing treatment dosage and duration of adjuvant S-1 plus oxaliplatin in patients with stage III colon cancer (SOAP trial) Suwa, Y.
32 S3 p. S161-S162
 article
120 P-190 Exploring possible predictors of survival in hepatocellular carcinoma Eiriz, I.
32 S3 p. S164-S165
 article
121 P-44 Expression and clinical significance of B cell translocation gene 2 in esophageal squamous cell carcinoma Wang, W.
32 S3 p. S110-S111
 article
122 P-224 Expression of major components of the exosome biogenesis pathway is deregulated in colorectal cancer and associated with clinical outcome: Preliminary results from an association study Kottorou, A.
32 S3 p. S175-S176
 article
123 P-65 Expression of TIMP-1 level as a diagnostic and prognostic factor in colon cancer patients: A systematic review Tandiono, J.
32 S3 p. S118-S119
 article
124 P-131 External validation of prognostic ALAN score in patients with inoperable bile duct cancer treated with second-line chemotherapy Giampieri, R.
32 S3 p. S143
 article
125 P-282 Factors predicting response to neoadjuvant chemotherapy in gastric cancer Kumar CG, P.
32 S3 p. S193
 article
126 P-256 Fibroblast-induced paradoxical PI3K pathway activation in colorectal cancer: Role of PTEN and potential implications for PI3K/mTOR inhibition Bazzichetto, C.
32 S3 p. S185
 article
127 P-113 FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine + cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement Bekaii-Saab, T.
32 S3 p. S137
 article
128 P-193 Final results of hepatectomy followed by adjuvant chemotherapy with 3-month capecitabine plus oxaliplatin for colorectal cancer liver metastases: A multicenter phase 2 study Hashida, H.
32 S3 p. S165-S166
 article
129 P-70 First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors Goyal, L.
32 S3 p. S120
 article
130 P-2 First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis Chan, S.
32 S3 p. S97
 article
131 P-207 FLOT in clinical practice: Retrospective analysis of an oncological center Fontes, R.
32 S3 p. S170
 article
132 P-47 5-fluorouracil bolus use in infusional regimens among oncologists: A survey by Brazilian Group of Gastrointestinal Tumors Peixoto, R.
32 S3 p. S112
 article
133 P-196 Frequency, biological behaviour and survival nomograms discrimination in non-KIT mutated gastrointestinal stromal tumors Alpoim, T.
32 S3 p. S166-S167
 article
134 P-11 GAME score in patients with liver metastases from colorectal cancer Ben Kridis, W.
32 S3 p. S100
 article
135 P-223 Gasdermin B predicts good prognosis and more macrophage infiltration Xu, F.
32 S3 p. S175
 article
136 P-195 Gastric adenocarcinoma classification: Association with clinicopathological features and overall survival in Moroccan patients Nshizirungu, J.
32 S3 p. S166
 article
137 P-289 Gastric and esophageal signet ring cell adenocarcinoma: A retrospective analysis of outcomes at Mayo Clinic Kusne, Y.
32 S3 p. S195
 article
138 P-3 Gastric cancer: 10-year survival Kshivets, O.
32 S3 p. S97
 article
139 P-122 Gastrointestinal side effects of morphine in cancer pain: A comparison between the smoking and non-smoking patients Hijri, F.
32 S3 p. S140
 article
140 P-216 Gender-specific genomic alterations among Hispanic patients with metastatic colorectal cancer Philipovskiy, A.
32 S3 p. S172-S173
 article
141 P-84 Genotype-fenotype correlation in patients with Lynch syndrome and colorectal cancer Garcia-Cuesta, J.
32 S3 p. S126
 article
142 P-1 Health-related quality of life of rectal cancer survivors treated with curative intent Ferreira, A.
32 S3 p. S97
 article
143 P-213 Helicobacter pylori babA gene evolution and adaptation in Colombian populations Guzman, K.
32 S3 p. S171-S172
 article
144 P-264 Helicobacter pylori SNPs associated with tetracycline, clarithromycin and amoxicillin resistance in Colombia Guzman, K.
32 S3 p. S187-S188
 article
145 P-159 HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction Maglakelidze, M.
32 S3 p. S154
 article
146 P-35 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of first-line treatment Ito, K.
32 S3 p. S108
 article
147 P-81 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment Kaneko, S.
32 S3 p. S125
 article
148 P-79 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment after anti-EGFR antibody Yoshikawa, A.
32 S3 p. S124
 article
149 P-54 Higher muscle mass is associated with better response to concurrent neoadjuvant chemoradiotherapy in rectal cancer patients Zhelev, K.
32 S3 p. S114-S115
 article
150 P-16 How does reinduction of first-line chemotherapy in patients with metastatic colorectal cancer impact outcomes? Experience from the University Hospital for Tumors, Zagreb, Croatia Pavlovic, M.
32 S3 p. S101
 article
151 P-7 How much can GIT cancer patients afford for effective and safe treatment? Aboelhassan, R.
32 S3 p. S98-S99
 article
152 P-75 Impact of an educational activity on the knowledge of oncologists regarding the latest clinical trial data on HER2-directed therapies for gastric and colorectal cancer Dorkhom, N.
32 S3 p. S122-S123
 article
153 P-119 Impact of circulating tumor DNA on clinical decisions in the adjuvant setting in patients with colorectal cancer Wookey, V.
32 S3 p. S139
 article
154 P-270 Impact of intestinal stoma on quality of life in Tunisian patients with colorectal cancer Melliti, R.
32 S3 p. S189-S190
 article
155 P-294 Impact of surgical margin status on the survival outcome after surgical resection of gastric cancer: A systematic review and meta-analysis Jiang, Z.
32 S3 p. S197
 article
156 P-82 Impact of type 2 diabetes mellitus in overall survival and clinical features of Latin patients with colorectal cancer: A 15-year follow-up Calderillo-Ruiz, G.
32 S3 p. S125-S126
 article
157 P-293 Implementation of Medic Assistant: Solutions in a digital cloud supporting medical staff in their daily work with oncological patients during the SARS-COV2 pandemic Kędzierska, M.
32 S3 p. S196-S197
 article
158 P-288 Individual drug-screening and heterogeneity analyses of patient-derived tumoroids: A roadmap to improving therapy in pancreatic cancer Nitschke, C.
32 S3 p. S195
 article
159 P-128 Influence of anti-diabetic medications on the outcomes of patients with pancreatic ductal adenocarcinoma and type 2 diabetes mellitus Pretta, A.
32 S3 p. S142
 article
160 P-150 Insights into the gastric and oesophageal cancer patient experience: Results of a pan-European patient survey Maravic, Z.
32 S3 p. S150
 article
161 P-46 Integrated transcriptomics and the exploration of cancer-promoting genes CDKN3 in esophageal squamous cell cancer Pan, Y.
32 S3 p. S111
 article
162 P-149 Integrative analysis of the genomic and transcriptomic landscape identifies novel key genes as a therapeutic target in bile duct cancer Salati, M.
32 S3 p. S150
 article
163 P-69 Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience Rizzo, A.
32 S3 p. S120
 article
164 P-267 Interleukin-8 levels as a predictor of colorectal cancer patient prognosis Conciatori, F.
32 S3 p. S188-S189
 article
165 P-247 In vivo feasibility study of a robotic arm-assisted endoscopic submucosal dissection for early gastric cancer Jeen, Y.
32 S3 p. S183
 article
166 P-110 Is dexamethasone necessary as a prophylactic antiemetic prior to gemcitabine plus nab-paclitaxel therapy? Murata, S.
32 S3 p. S136
 article
167 P-230 Is stereotactic microwave ablation of resectable colorectal liver metastasis an alternative for liver resection in the Covid-19 pandemic? Chapelle, T.
32 S3 p. S177-S178
 article
168 P-30 Is vitamin D status known in patients with advanced pancreatic adenocarcinoma? Uña Cidón, E.
32 S3 p. S106
 article
169 P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation Tabernero, J.
32 S3 p. S121
 article
170 P-183 Laparoscopic colorectal resection for elderly patients aged 80 years or older: A propensity score analysis Inada, R.
32 S3 p. S162
 article
171 P-40 Lenvatinib versus sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study Rimini, M.
32 S3 p. S109
 article
172 P-220 Linc01088 promotes the progression and tumor immune escape in colorectal cancer by sponging multiple microRNAs Wang, S.
32 S3 p. S174
 article
173 P-41 Lipopolysaccharides promote metastasis via acceleration of glycolysis by the nuclear factor-κB/Snail/Hexokinase3 signaling axis in colorectal cancer Xu, F.
32 S3 p. S109-S110
 article
174 P-12 Long intergenic non-protein coding RNA 1094 regulates the progression of gastric cancer Ge, O.
32 S3 p. S100
 article
175 P-249 Long-term oncologic safety of self-expandable metal stent as a bridge to surgery for obstructing colon cancer Shim, J.
32 S3 p. S183
 article
176 P-281 Low proliferation indexes in colorectal cancer in Tunisian patients: Association with rectal localization, mucinous histological type and stage Wider, D.
32 S3 p. S193
 article
177 P-127 Lymphocyte to monocyte ratio as a prognostic factor in stage IV pancreatic ductal adenocarcinoma naive patients before gemcitabine-nab-paclitaxel chemotherapy Pretta, A.
32 S3 p. S142
 article
178 P-138 Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer Catenacci, D.
32 S3 p. S146
 article
179 P-63 MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer Janjigian, Y.
32 S3 p. S118
 article
180 P-241 Metastatic lymph node ratio as an addition to the nodal evaluation of TNM staging: A new sight for prevention of stage migrations Tanal, M.
32 S3 p. S181
 article
181 P-132 Molecular profiling of KIT and PDGFRA in Chilean GIST patients: A Latin-American perspective Muñoz-Medel, M.
32 S3 p. S143-S144
 article
182 P-164 MONEO: A phase II study of avelumab plus FLOT in the peri-operative treatment for patients with resectable gastric or gastroesophageal junction cancer Alsina, M.
32 S3 p. S155-S156
 article
183 P-174 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress Strickler, J.
32 S3 p. S159
 article
184 P-273 Mucinous colorectal cancer in Tunisian patients: A controversial clinicopathological type Guettiti Tounsi, H.
32 S3 p. S190-S191
 article
185 P-251 Multidisciplinary challenge for the oncologist and surgeon: Gastrointestinal stromal tumors. Follow-up of a tertiary surgical department Baran, E.
32 S3 p. S184
 article
186 P-290 Mutant allele specific imbalance in RAS as prognostic marker in colorectal cancer Kirshenboim, Y.
32 S3 p. S195-S196
 article
187 P-141 Neoadjuvant chemotherapy with docetaxel, nedaplatin, and 5-FU for resectable esophageal cancer: A single center retrospective study Shindo, S.
32 S3 p. S147
 article
188 P-265 Neoadjuvant radiotherapy for locally advanced rectal cancer during the first wave of COVID19 pandemic: Guy’s cancer cohort experience Sachdeva, A.
32 S3 p. S188
 article
189 P-124 Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma Su, Y.
32 S3 p. S141
 article
190 P-8 Nutritional status among colorectal cancer patients in Tunisia Zribi, A.
32 S3 p. S99
 article
191 P-49 Oesophageal neuroendocrine carcinoma: Retrospective evaluation of outcomes from a UK tertiary centre Tilby, M.
32 S3 p. S112
 article
192 P-266 Oncological outcomes of self-expanding metal stent as a bridge to surgery for obstructive left-sided colon cancer Gomez Fernandez, L.
32 S3 p. S188
 article
193 P-166 Operative versus nonoperative treatment for stage 0 rectal cancer following chemoradiation therapy Aires, F.
32 S3 p. S156
 article
194 P-215 Outcomes following surgery for resectable pancreatic neuroendocrine tumors: A Brazilian single institutional experience Arra, D.
32 S3 p. S172
 article
195 P-62 Overall survival of patients with pancreatic cancer Flores, C.
32 S3 p. S117-S118
 article
196 P-52 Overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumor location Kasper, S.
32 S3 p. S114
 article
197 P-29 Pancreatic cancer during the COVID-19 pandemic: A high-volume Polish centre experience Durlik, M.
32 S3 p. S106
 article
198 P-36 Pancreatic cancer in times of the pandemic Una Cidon, E.
32 S3 p. S108
 article
199 P-208 Pancreatic neuroendocrine neoplasia: Experience of a comprehensive cancer center Coelho, S.
32 S3 p. S170
 article
200 P-234 Participation of screening and barriers in Chinese patients with advanced colorectal cancer before diagnosis: A national multi-center cross-sectional study Liu, Y.
32 S3 p. S179
 article
201 P-137 Patient baseline characteristics in the PROMETCO study: A real-world, prospective longitudinal cohort on the continuum of care of metastatic colorectal cancer Koopman, M.
32 S3 p. S145-S146
 article
202 P-233 Patient information and management by eHealth intervention during colon cancer Jorge, T.
32 S3 p. S178-S179
 article
203 P-135 Pembrolizumab/quavonlimab coformulation in combination with lenvatinib in advanced hepatocellular carcinoma: Phase 2 trial in progress Li, D.
32 S3 p. S144-S145
 article
204 P-148 Perfect concordance between blood-based and normal tissue-based dihydropyrimidine dehydrogenase polymorphisms suggests that pharmacogenetic screening could be contextual to tumour molecular profiling Morelli, C.
32 S3 p. S149
 article
205 P-111 PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification Tabernero, J.
32 S3 p. S136-S137
 article
206 P-18 Phase Ib study of niraparib plus tebotelimab in patients with advanced or metastatic gastric cancer after prior treatment failure Xu, R.
32 S3 p. S102
 article
207 P-228 Phase II multicentric randomized controlled trial to compare first-line treatment with FOLFOX6m + mAB alone or in combination with liver chemoembolization (Lifepearls-Irinotecan) in poor prognosis colorectal cancer with liver-limited disease Paez, D.
32 S3 p. S177
 article
208 P-261 Phase I study of multiple kinase inhibitor, TT-00420, in advanced, refractory cholangiocarcinoma Piha-Paul, S.
32 S3 p. S186-S187
 article
209 P-260 Plasma exRNA-based identification of novel biomarkers in early gastric cancer Xing, S.
32 S3 p. S186
 article
210 P-105 POLO: Patient-centred outcomes with maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer Kindler, H.
32 S3 p. S134
 article
211 P-143 Polyphyllin Ⅱ and resiquimod-loaded injectable hydrogels promote the polarization of tumor-associated macrophages and enhance gastric cancer immunotherapy Yang, Y.
32 S3 p. S148
 article
212 P-78 Post hoc analysis in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function in the phase 3 REFLECT study of lenvatinib vs sorafenib Huynh, J.
32 S3 p. S123-S124
 article
213 P-120 Pre-assessment tool predicting complication following oesophagogastric resection: Sarcopenia or incremental shuttle walk test Siddaiah-Subramanya, M.
32 S3 p. S139
 article
214 P-287 Preclinical evaluation of alpelisib (PI3K inhibitor) and its synergistic effect in combination with ribociclib (CDK 4/6 inhibitor) in colorectal cancer Aslam, R.
32 S3 p. S194-S195
 article
215 P-10 Prevalence and risk factors of chronic neuropathy in 225 colorectal cancer patients treated with oxaliplatin-based regimens in Tunisia Zribi, A.
32 S3 p. S99-S100
 article
216 P-198 Prevalence of deleterious DPYD variants in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy Cardone, C.
32 S3 p. S167
 article
217 P-202 Primary tumour location and efficacy of first-line anti-EGFR agents in the treatment of RAS wild-type metastatic colorectal cancer Marinho, J.
32 S3 p. S168-S169
 article
218 P-4 Prognostic and therapeutic values of tumor-infiltrating lymphocytes in localized colon cancer Ben Nasr, S.
32 S3 p. S98
 article
219 P-53 Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis Broadbent, R.
32 S3 p. S114
 article
220 P-50 Prognostic factors in patients receiving trifluridine/tipiracil for refractory metastatic colorectal cancer in the real-life setting: The ROS study García-Alfonso, P.
32 S3 p. S113
 article
221 P-283 Prognostic factors in the evaluation of stage II/III squamous cell carcinoma of the anus treated with chemoradiation Gramaça, J.
32 S3 p. S193
 article
222 P-191 Prognostic factors of colorectal cancer liver metastasectomy Costa, I.
32 S3 p. S165
 article
223 P-67 Prognostic implication of HER2 overexpression in surgically treated patients with gastric cancer Enkhbat, E.
32 S3 p. S119
 article
224 P-232 Prognostic inflammatory and microRNA biomarkers in stage IV colorectal cancer patients Nassar, F.
32 S3 p. S178
 article
225 P-9 Prognostic role of preoperative inflammation parameters in predicting postoperative complications of colorectal cancer surgery Melliti, R.
32 S3 p. S99
 article
226 P-188 Propensity score analysis of outcomes following laparoscopic or open radical resection for gallbladder carcinoma in T2 and T3 stages Dou, C.
32 S3 p. S164
 article
227 P-172 PTHrP and SPARC expressions in human colorectal cancer: An in silico analysis Carriere, P.
32 S3 p. S158
 article
228 P-219 Real-life experience with chemotherapy plus biologics in first-line treatment of right-sided, RAS wild-type, metastatic colon cancer: A multicenter Onco-Colon Turkey study Ç. Arslan,
32 S3 p. S174
 article
229 P-87 Real-world data of nivolumab in advanced hepatocellular carcinoma: A multi-centric and retrospective study Sardinha, M.
32 S3 p. S127
 article
230 P-34 Real-world efficacy and safety of immune checkpoint inhibitors in microsatellite unstable or mismatch repair deficient gastrointestinal tumors Martínez Lago, N.
32 S3 p. S107
 article
231 P-31 Real-world efficacy and safety of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies Martínez Lago, N.
32 S3 p. S106-S107
 article
232 P-21 Real-world outcomes in patients with advanced or metastatic gastric adenocarcinoma in the United States Beachler, D.
32 S3 p. S103
 article
233 P-163 Real-world outcomes of cisplatin, capecitabine and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma Waldron, N.
32 S3 p. S155
 article
234 P-130 Real-world outcomes of patients with colorectal liver metastases treated with transarterial radioembolization: Results from CIRT, a large European, prospective multi-centre, observational study Schaefer, N.
32 S3 p. S143
 article
235 P-180 Rectal cancer in the elderly: Characteristics, management and outcomes from a single centre retrospective cohort review Hamed, R.
32 S3 p. S161
 article
236 P-42 Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies as treatment option in vulnerable older patients with metastatic colorectal cancer: A retrospective cohort study Rosati, G.
32 S3 p. S110
 article
237 P-178 Rego-Nivo II-III: Proof-of-concept phase II trial for the treatment of HCC refractory to chemotherapy after the 2nd line Ben Merabet, Y.
32 S3 p. S160-S161
 article
238 P-26 Regorafenib versus cabozantinib as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: Matching-adjusted indirect comparison analysis Casadei Gardini, A.
32 S3 p. S105
 article
239 P-85 Relationship between microsatellite instability and neoadjuvant chemotherapy response in gastric or gastroesophageal junction cancer: A meta-analysis Ergun, Y.
32 S3 p. S126-S127
 article
240 P-203 Relationship of myelotoxicity and of gastrointestinal toxicity with the treatment outcome in trials of second-line chemotherapy of patients with metastatic colorectal cancer Venturino, A.
32 S3 p. S169
 article
241 P-61 Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073 Sangro, B.
32 S3 p. S117
 article
242 P-221 Repurposing disulfiram as treatment for metastatic colorectal cancer: An investigator-initiated clinical phase II trial Tarpgaard, L.
32 S3 p. S174-S175
 article
243 P-252 Residual fibrosis after treatment with anti-epidermal growth factor receptor or bevacizumab in colorectal liver metastases and its correlation with survival: A retrospective pooled analysis Hernández-Yagüe, X.
32 S3 p. S184
 article
244 P-68 Response to neoadjuvant chemotherapy in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma with FLOT-regimen in our setting Garcia Grove, C.
32 S3 p. S119
 article
245 P-33 Results of initial DPYD screening for cancer patients receiving fluoropyrimidines Bolaños Naranjo, M.
32 S3 p. S107
 article
246 P-201 Retrospective evaluation of patients with colorectal cancer with metastasis in the central nervous system: Clinical and epidemiological prognostic factors Sá, D.
32 S3 p. S168
 article
247 P-77 Risk factors and clinical outcomes of post-gastrectomy sarcopenia newly developed after curative resection for gastric cancer Kim, B.
32 S3 p. S123
 article
248 P-211 Risk of diabetes in subjects with positive fecal immunochemical test: A nationwide population-based study Lee, H.
32 S3 p. S171
 article
249 P-104 Risk of nausea and vomiting in a real-world data cohort of chemotherapy-treated patients with metastatic gastric or gastroesophageal junction adenocarcinoma by medical history of gastrectomy de Vogel, S.
32 S3 p. S133-S134
 article
250 P-254 Role of neutrophil-lymphocyte ratio in the prognosis of stomach carcinoma undergoing curative resection Ambre, S.
32 S3 p. S185
 article
251 P-244 Role of preoperative contrast-enhanced computed tomography in staging of gastric cancer in patients undergoing upfront surgery with curative intent Colney, L.
32 S3 p. S182
 article
252 P-22 Role of timing to laparoscopic or robotic surgery after neoadjuvant chemoradiotherapy for rectal cancer: The TiMiSNAR trial Monsellato, I.
32 S3 p. S103
 article
253 P-153 Safety and effectiveness of sorafenib in elderly patients diagnosed with advanced hepatocellular carcinoma in a monographic oncologic center Vidales Sepulveda, Z.
32 S3 p. S151
 article
254 P-142 Safety and efficacy of apatinib for non-surgical advanced esophageal cancer: A real-world study Sun, C.
32 S3 p. S147
 article
255 P-91 Safety and efficacy of perioperative FLOT in elderly patients: Real-world data Baleiras, M.
32 S3 p. S128-S129
 article
256 P-189 Safety and feasibility of liposomal irinotecan for unresectable pancreatic adenocarcinoma: Real-world experience in a Japanese cohort Sakai, A.
32 S3 p. S164
 article
257 P-152 Sarcopenia in advanced colorectal cancer patients treated with trifluridine/tipiracil Malik, M.
32 S3 p. S151
 article
258 P-32 SARS-CoV-2 pandemic and delayed presentation of gastrointestinal cancer patients: A retrospective evaluation and the impact on clinical outcome Ida Bagus, B.
32 S3 p. S107
 article
259 P-268 Seaweed laminaria japonica peptides possess strong anti-liver cancer effects Chen, H.
32 S3 p. S189
 article
260 P-276 Sex and regorafenib toxicity in refractory colorectal cancer: A safety analysis of the RegARd-C trial Vandeputte, C.
32 S3 p. S191-S192
 article
261 P-37 SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: Biliary tract cancer cohort (trial in progress) Bekaii-Saab, T.
32 S3 p. S108-S109
 article
262 P-214 Should patients with active gastrointestinal tumors receive thromboprophylaxis to avoid the negative clinical consequences of CAT? Sub-analysis of ACT4CAT study Tsoukalas, N.
32 S3 p. S172
 article
263 P-272 Significance of adding oxaliplatin to postoperative adjuvant chemotherapy in elderly patients with colorectal cancer Nagata, Y.
32 S3 p. S190
 article
264 P-134 Social determinants of health are risk factors for early onset colorectal cancer in Appalachia Oelsner, W.
32 S3 p. S144
 article
265 P-88 Sorafenib for hepatocellular carcinoma in real life Una Cidon, E.
32 S3 p. S127
 article
266 P-80 Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON Peck-Radosavljevic, M.
32 S3 p. S124-S125
 article
267 P-6 Spatio-temporal distribution pattern of pancreatic cancer mortality rate in Peru between 2003-2017 Flores, C.
32 S3 p. S98
 article
268 P-262 Staining plasma with lipophilic dye followed by size-exclusion chromatography, immune-capturing and on-bead flow cytometry is a highly sensitive approach to quantifying colorectal cancer derived extracellular nanovesicles Nikiforova, N.
32 S3 p. S187
 article
269 P-218 STAT3 signaling inhibition in regulatory T cells improves immune response to RT in PDAC Piper, M.
32 S3 p. S173
 article
270 P-194 Study of efficacy and safety of combination of octreotide acetate LAR with lenvatinib as second-line therapy in patients with advanced G1-G2 NETs of non-pancreatic origin Goel, V.
32 S3 p. S166
 article
271 P-48 Study of paclitaxel and ramucirumab as second-line therapy after failure of FOLFOX-6 regimen in metastatic stomach carcinoma patients Goel, V.
32 S3 p. S112
 article
272 P-123 Survival analysis based on the grade of neutropenia in patients with metastatic colorectal cancer treated with trifluridine-tipiracil Aviñó Tarazona, V.
32 S3 p. S140
 article
273 P-206 Survival comparison of first-line therapies in locally advanced or metastatic pancreatic cancer: A Portuguese oncology unit experience Gameiro-dos-Santos, R.
32 S3 p. S169
 article
274 P-204 Survival improvement from the addition of biologics is not affected by performance status in patients with metastatic colorectal cancer: A meta-analysis Colloca, G.
32 S3 p. S169
 article
275 P-101 Survival of early-onset gastric signet ring cell carcinoma in the Korean population between 2010 and 2015: Analysis of the Korea Central Cancer Registry database Kim, H.
32 S3 p. S132
 article
276 P-117 Survival outcomes following systemic chemotherapy in stage IVA/B high-grade mucinous appendiceal cancer after unsuccessful cytoreductive surgery and hyperthermic intraperitoneal chemotherapy Baron, E.
32 S3 p. S138
 article
277 P-118 Survival outcomes of adjuvant chemotherapy in stage IVA/B high-grade appendiceal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy Baron, E.
32 S3 p. S139
 article
278 P-229 Systematic review and pooled analysis of locoregional therapies in patients with intrahepatic cholangiocarcinoma Edeline, J.
32 S3 p. S177
 article
279 P-231 Systemic inflammatory biomarkers and their association with survival in gastroesophageal cancer patients: A retrospective single-center analysis Puhr, H.
32 S3 p. S178
 article
280 P-271 The anti-tumor effect of Curcuma phaeocaulis cyclopeptide in human hepatoma HepG2 cells Chen, H.
32 S3 p. S190
 article
281 P-93 The characteristics and prognosis of extragastrointestinal stromal tumors: A single center retrospective analysis of 31 patients Mu, M.
32 S3 p. S129
 article
282 P-255 The clinical significance of the gut microbiota in RAS wild-type metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies in combination with chemotherapy – preliminary results Lewandowski, T.
32 S3 p. S185
 article
283 P-89 The correlation between adverse events and survival benefits of donafenib in the first-line treatment of advanced hepatocellular carcinoma Bi, F.
32 S3 p. S128
 article
284 P-240 The diagnosis and treatment of advanced colorectal cancer in China: A national multi-center cross-sectional study Xu, H.
32 S3 p. S180-S181
 article
285 P-161 The diagnostic methods for detection of Helicobacter pylori infection: A comparative approach to invasive methods Castro-Valencia, F.
32 S3 p. S154-S155
 article
286 P-263 The effects of co-administration of erlotinib and apatinib in the treatment oesophageal squamous cell carcinoma Lin, Y.
32 S3 p. S187
 article
287 P-27 The efficacy and safety of XELOX/SOX plus bevacizumab as neoadjuvant chemotherapy for locally advanced rectal cancer compared with XELOX/SOX: A retrospective study Sakaguchi, N.
32 S3 p. S105
 article
288 P-83 The efficacy of chemotherapy for gastric cancer with early recurrence during or after adjuvant S-1 Kumagai, K.
32 S3 p. S126
 article
289 P-212 The genetic and epigenetic abnormalities of plasma cfDNA as liquid biopsy biomarkers for diagnosis and prognosis stratification of pancreatic ductal adenocarcinoma Wang, Y.
32 S3 p. S171
 article
290 P-74 The impact of first-line chemotherapy in elderly patients with advanced pancreatic cancer: A mono-institutional retrospective study Maratta, M.
32 S3 p. S122
 article
291 P-64 The impact of sarcopenia on overall survival among cholangiocarcinoma patients: A systematic review and meta-analysis Marcella, E.
32 S3 p. S118
 article
292 P-102 The importance of maintenance chemotherapy in the first and second lines of treatment of metastatic colorectal cancer Gridnev, D.
32 S3 p. S132-S133
 article
293 P-295 The importance of sphingosine kinase 1 isoform expression in the gut-liver axis Chen, H.
32 S3 p. S197
 article
294 P-86 The importance of sphingosine kinase 1 isoform expression in the gut-liver axis Chen, H.
32 S3 p. S127
 article
295 P-197 The influence of proton pump inhibitor utilization on the pathological response of rectal cancer: A multicenter study by the Sociedad Latino Americana de Oncologia Gastrointestinal (SLAGO) Cesca, M.
32 S3 p. S167
 article
296 P-217 The knowledge and awareness for colorectal cancer in advanced colorectal cancer patients in China: A national multicenter study Xu, H.
32 S3 p. S173
 article
297 P-92 The neuroendocrine tumor diagnostic process and the role of gastrointestinal specialists Leyden, S.
32 S3 p. S129
 article
298 P-14 The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with pancreatic cancer Bengueddach, A.
32 S3 p. S100
 article
299 P-291 The prognostic and predictive factors for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy Acun, M.
32 S3 p. S196
 article
300 P-151 The prognostic value of TCF1+CD8+T cell in primary small cell carcinoma of the esophagus Ma, L.
32 S3 p. S150-S151
 article
301 P-73 The role of site of metastatic resection in metastatic colorectal cancer patients: A mono-institutional cohort study Camarda, F.
32 S3 p. S122
 article
302 P-39 The role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib Rimini, M.
32 S3 p. S109
 article
303 P-5 The use of complementary and alternative medicine among colorectal cancer patients in Tunisia Zribi, A.
32 S3 p. S98
 article
304 P-133 The watch-and-wait approach in stage IV rectal cancer patients: A good alternative for TME surgery? Custers, P.
32 S3 p. S144
 article
305 P-279 Thromboembolic complications in colorectal cancers Mkedder, N.
32 S3 p. S192-S193
 article
306 P-285 Treatment outcomes with sorafenib in advanced hepatocellular carcinoma: A single-center retrospective study Prejac, J.
32 S3 p. S194
 article
307 P-226 Trifluridin/tipiracil and regorafenib sequencing in Slovenian patients with metastatic colorectal cancer Mesti, T.
32 S3 p. S176
 article
308 P-292 Tumor downstaging as an associated factor with recurrence of disease in patients with operated rectal cancer after neoadjuvant chemoradiotherapy: Real-world data from Peru Motta, R.
32 S3 p. S196
 article
309 P-169 Tumor-infiltrating lymphocytes in colorectal cancer: A clinical outcome predictor Vitorino, M.
32 S3 p. S157
 article
310 P-184 Underlining mechanism for the efficacy of tumor treating fields (TTFields) concomitant with sorafenib for treatment of hepatocellular carcinoma Davidi, S.
32 S3 p. S162-S163
 article
311 P-94 Unicentric real-world data from esophageal cancer neoadjuvant treatment according to the CROSS trial protocol Mendonça, J.
32 S3 p. S129-S130
 article
312 P-162 Universally adopted vitamin D deficiency cutoff of 10 ng/mL is optimal for metastatic colorectal cancer prognostication and correlated with neutrophil/lymphocyte ratio Rofei, M.
32 S3 p. S155
 article
313 P-38 Unmet needs and concerns of Russian patients with CRC: Analysis of Russian internet postings Khomitskaya, Y.
32 S3 p. S109
 article
314 P-97 Updated results of HGCSG1603: A phase 2 trial of ramucirumab plus irinotecan combination therapy as second-line treatment for patients with advanced gastric cancer Nakamura, M.
32 S3 p. S131
 article
315 P-297 Upfront dihydropyrimidine dehydrogenase deficiency detection to secure 5-FU or capecitabine administration: Application to colorectal cancer patients Mkedder, N.
32 S3 p. S198
 article
316 P-57 US real-world ramucirumab and immune checkpoint inhibitor treatment sequences in advanced gastric, gastroesophageal junction, or esophageal cancer Liepa, A.
32 S3 p. S116
 article
317 P-186 Vimentin-positive circulating tumor cells as diagnostic and prognostic biomarkers in biliary tract cancer patients Han, S.
32 S3 p. S163
 article
318 P-187 Watch-and-wait strategy for DNA mismatch repair-deficient/microsatellite instability-high rectal cancer with a clinical complete response after neoadjuvant immunotherapy: An observational cohort study Wang, Q.
32 S3 p. S163-S164
 article
319 P-116 What have we learned about of trifluridine/tipiracil (TAS-102)? Real World Data at four GEODA hospitals (Spain) Martínez Pérez, J.
32 S3 p. S138
 article
320 P-160 Young Latin American population with colorectal cancer: Characteristics of bad prognosis Calderillo-Ruiz, G.
32 S3 p. S154
 article
321 SO-19 A multicenter phase Ⅱ trial of trifluridine/tipiracil in combination with cetuximab in RAS wild-type metastatic colorectal cancer patients refractory to prior anti-EGFR antibody therapy: The WJOG8916G trial Masuishi, T.
32 S3 p. S210-S211
 article
322 SO-9 Analysis of the immune-related endpoints of the mismatch repair–deficient non-endometrial solid cancers cohort from the GARNET study André, T.
32 S3 p. S205-S206
 article
323 SO-10 An open-label, multi-centre, phase Ib/II study of PI3Kβ selective inhibitor GSK2636771 administered in combination with paclitaxel in patients with advanced gastric cancer having alterations in PI3K/Akt pathway Jung, M.
32 S3 p. S206
 article
324 SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer Chung, H.
32 S3 p. S215-S216
 article
325 SO-24 Circulating tumor DNA variant allelic fraction as a surrogate for disease burden estimation in patients with RAS wild-type metastatic colorectal cancer: A secondary endpoint of the VALENTINO study Manca, P.
32 S3 p. S212
 article
326 SO-28 Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC Aderka, D.
32 S3 p. S214
 article
327 SO-29 Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive gastrointestinal cancer: An expanded dataset Boni, V.
32 S3 p. S214-S215
 article
328 SO-30 Efficacy and safety of neoadjuvant short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma: Averectal study Shamseddine, A.
32 S3 p. S215
 article
329 SO-25 Global rise in early-onset colorectal cancer: An association with antibiotic consumption? Perrott, S.
32 S3 p. S213
 article
330 SO-8 Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair deficient advanced solid tumors: Results from the KEYNOTE-158 study Maio, M.
32 S3 p. S205
 article
331 SO-21 Impact of timing of perioperative chemotherapy on survival outcomes among patients with colorectal liver metastases: A propensity score matching of the national cancer database Baidoun, F.
32 S3 p. S211
 article
332 SO-22 Importance order of risk factors for mortality in colon cancer stage II: A multivariate adaptive regression spline (MARS) analysis Fabregas, J.
32 S3 p. S211-S212
 article
333 SO-26 In-silico Lynch syndrome-related neoantigens prediction for a dendritic cell-based cancer prevention vaccine Bayó, C.
32 S3 p. S213
 article
334 SO-11 KISIMA-01 trial: Safety, tolerability and immunogenicity of ATP128 with or without ezabenlimab (BI 754091) in patients with stage IV colorectal cancer – preliminary results from a phase 1b study Kopetz, S.
32 S3 p. S206-S207
 article
335 SO-13 KRAS-G12C mutations in a Nordic cohort of 1441 metastatic colorectal cancer patients Osterlund, E.
32 S3 p. S207-S208
 article
336 SO-6 Microarchitectural changes in regional lymph nodes after chemotherapy in oesophageal cancer: Results from the UK MRC OE02 trial Kloft, M.
32 S3 p. S204
 article
337 SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 André, T.
32 S3 p. S213-S214
 article
338 SO-2 Pancreatic cancer in HIV versus non-HIV population: Analysis of demographics, outcomes and healthcare utilization from a national sample Sherazi, S.
32 S3 p. S202
 article
339 SO-4 Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response Abou-Alfa, G.
32 S3 p. S203-S204
 article
340 SO-20 Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study Antoniotti, C.
32 S3 p. S211
 article
341 SO-15 Quality of life and physical functioning in older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study Liposits, G.
32 S3 p. S208
 article
342 SO-16 Quality of life in Finnish metastatic colorectal cancer patients actively treated with the aim of maximizing resection and/or local ablative therapy (RAXO-study NCT01531595) Osterlund, P.
32 S3 p. S209
 article
343 SO-18 Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: Final results according to duration of treatment from the phase IIIb, international, open-label, early-access PRECONNECT study Taieb, J.
32 S3 p. S210
 article
344 SO-23 The genomic temporal heterogeneity of circulating tumor DNA in metastatic colorectal cancer under first-line treatment Huang, Y.
32 S3 p. S212
 article
345 SO-17 The global POLAR program: Top-line results of placebo-controlled studies of calmangafodipir on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy Qvortrup, C.
32 S3 p. S209-S210
 article
346 SO-1 The impact of COVID-19 on daily practice patterns in the third-line setting for patients with metastatic colorectal cancer: Results of a real-world survey Prager, G.
32 S3 p. S202
 article
347 SO-7 The prognostic and predictive role of preoperative chemotherapy sensitivity in gastric adenocarcinoma: A study of national cancer database Deng, L.
32 S3 p. S204-S205
 article
348 SO-14 The prognostic impact of KRAS G12C mutation in patients with metastatic colorectal cancer: A multicenter retrospective observational study Matsubara, Y.
32 S3 p. S208
 article
349 SO-3 Treatment sequences and prognostic factors in metastatic pancreatic ductal adenocarcinoma: Univariate and multivariate analyses of a real-world study in Europe Taieb, J.
32 S3 p. S203
 article
350 SO-5 Tumor inflammation and proliferative status as biomarkers in gastroesophageal adenocarcinoma Mukherjee, S.
32 S3 p. S204
 article
351 SO-12 Updated safety, efficacy, and PK results from an open-label, multicenter, phase I/II study of avapritinib in Chinese patients with unresectable or metastatic gastrointestinal stromal tumors Li, J.
32 S3 p. S207
 article
352 Table of Contents
32 S3 p. iv
 article
353 Title Page
32 S3 p. iii
 article
                             353 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands